Santalum album serum - Santalis

Drug Profile

Santalum album serum - Santalis

Alternative Names: Albuterpenoid - Santalis Pharmaceuticals; East Indian Sandalwood Oil (EISO) serum; SAN 021

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Santalis Pharmaceuticals
  • Class Anti-infectives; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Plaque psoriasis

Most Recent Events

  • 19 Dec 2016 Santalis Pharmaceuticals, Dermatology Research Center of San Antonio, DermResearch, Clinical Trials of Texas and ClinDatrix plan a phase II trial for Plaque psoriasis in USA (Topical) (NCT03000608)
  • 14 Dec 2016 Santalis Pharmaceuticals and Fremantle Dermatology plan a phase II trial for Plaque psoriasis in Australia (Topical) (NCT02993328)
  • 01 Sep 2016 Santalis Pharmaceuticals has patent protection for sandalwood oil-containing compositions in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top